HER2 Support Group Forums - View Single Post - New Generation of Treatments Show Promise For Cancer Patient

07-22-2003, 04:23 AM

Armed with information about the function and capabilities of currently approved cancer therapies researchers are beginning to develop more potent and successful treatments according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research (AACR). "Scientists have used today's standard drugs to research and develop a new class of effective therapies for cancer sufferers " said Karen Antman M.D. Chief Division of Medical Oncology Columbia University; director of Columbia's Herbert Irving Comprehensive Cancer Center; and AACR president-elect. "These preliminary therapies may increase survival for a number of common cancers."

The "Efficacy of Radioimmunotherapy with Radiolabeled HerceptinTM in Combination with Gemcitabine in the Treatment of Intraperitoneal Disease" is covered in Abstract #5787.

"MAC-321: A Novel Taxane with Greater Efficacy than Paclitaxel and Docetaxel In Vitro and In Vivo" is covered in Abstract #5779.

07-22-2003, 04:23 AM	#1
Paul C. Guest Posts: n/a	Armed with information about the function and capabilities of currently approved cancer therapies researchers are beginning to develop more potent and successful treatments according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research (AACR). "Scientists have used today's standard drugs to research and develop a new class of effective therapies for cancer sufferers " said Karen Antman M.D. Chief Division of Medical Oncology Columbia University; director of Columbia's Herbert Irving Comprehensive Cancer Center; and AACR president-elect. "These preliminary therapies may increase survival for a number of common cancers." The "Efficacy of Radioimmunotherapy with Radiolabeled HerceptinTM in Combination with Gemcitabine in the Treatment of Intraperitoneal Disease" is covered in Abstract #5787. "MAC-321: A Novel Taxane with Greater Efficacy than Paclitaxel and Docetaxel In Vitro and In Vivo" is covered in Abstract #5779.